Project Grant R21DA062022
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$847K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38163, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing new treatments for opioid use disorder. The $1,717,200 award, spanning August 1, 2024 to May 31, 2029, will enable researchers at the University of...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,134,928 to the Regents of the University of Minnesota to develop novel, brain-penetrant, small molecule biased allosteric modulators (BAMs) of the neurotensin receptor 1 (NTSR1) to attenuate relapse to opioid seeking in individuals with opioid use disorder (OUD). The research aims to validate NTSR1 as a drug target for OUD treatment...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $945,966 to Rowan University to study the potential of the GPR83 receptor pathway as a target for reducing the abuse liability of opioid medications. The research aims to unravel the neurobiological mechanisms by which the GPR83 receptor and its endogenous ligand PEN interact with the mu-opioid receptor (MOR) in the periaqueductal gray...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $267,310 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Minnesota. The award will fund research to investigate the role of the neuropeptide VGF and its derived peptide TLQP-62 in facilitating synaptic plasticity in the nucleus accumbens and their contribution to opioid withdrawal behaviors. Key research activities include...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
This Project Grant award of $1,539,260 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to study the role of the kappa opioid receptor (KOR) system in opioid use disorder (OUD). The key objectives are to: Use PET imaging to compare KOR availability in early abstinent individuals with moderate-to-severe OUD (N=40) versus healthy controls (N=30). Examine the clinical and transdiagnostic relevance of KOR,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800 to the University of Florida to conduct research on pharmacologically targeting novel modulators of opioid signaling. The overarching goal is to dissociate the behavioral effects associated with opioid receptor activation to curb the development of dependence and tolerance. The research will involve using high-throughput screening...